SARS-CoV-2 vaccine-related adverse events in Zimbabwe: The need to strengthen pharmacovigilance in resource-limited settings
Pharmacoepidemiol Drug Saf
.
2022 Mar;31(3):379-380.
doi: 10.1002/pds.5393.
Epub 2021 Dec 26.
Authors
Grant Murewanhema
1
,
Tafadzwa Dzinamarira
2
3
,
Roda Madziva
4
,
Helena Herrera
5
,
Godfrey Musuka
2
Affiliations
1
Unit of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
2
ICAP at Columbia University, Harare, Zimbabwe.
3
School of Health Systems & Public Health, University of Pretoria, Pretoria, South Africa.
4
School of Sociology and Social Policy, University of Nottingham, Nottingham, UK.
5
School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
PMID:
34882894
DOI:
10.1002/pds.5393
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines*
COVID-19*
Humans
Pharmacovigilance
SARS-CoV-2
Zimbabwe / epidemiology
Substances
COVID-19 Vaccines